Autoimmune Diseases  >>  dapirolizumab pegol (CDP7657)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dapirolizumab pegol (CDP7657) / Biogen, UCB, Nektar Therap
NCT01093911: Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Completed
1
44
Europe
CDP7657, Placebo
UCB Pharma
Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases, Connective Tissue Disease
12/12
12/12
NCT01764594: Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Checkmark For systemic lupus erythematosus
Aug 2017 - Aug 2017: For systemic lupus erythematosus
Completed
1
24
Europe, RoW
CDP7657, Placebo
UCB Pharma, Biogen
Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases, Connective Tissue Disease
08/14
08/14

Download Options